These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Respiratory syncytial virus: different criteria for palivizumab use in different areas? Mitchell I South Med J; 2007 Jul; 100(7):661-2. PubMed ID: 17639741 [No Abstract] [Full Text] [Related]
31. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009. Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095 [TBL] [Abstract][Full Text] [Related]
32. Response to respiratory synctial virus. Hampp C; Winterstein AG South Med J; 2008 Feb; 101(2):212-3; author reply 213-4. PubMed ID: 18364631 [No Abstract] [Full Text] [Related]
33. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Checchia PA; Nalysnyk L; Fernandes AW; Mahadevia PJ; Xu Y; Fahrbach K; Welliver RC Pediatr Crit Care Med; 2011 Sep; 12(5):580-8. PubMed ID: 21200358 [TBL] [Abstract][Full Text] [Related]
34. Prophylaxis for respiratory syncytial virus bronchiolitis. Nadal D; Berger C; Aebi C; Kind C Lancet; 1999 Dec; 354(9194):1997. PubMed ID: 10622321 [No Abstract] [Full Text] [Related]
35. Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey. Paes B; Lanctôt K Turk J Pediatr; 2013; 55(5):564-7. PubMed ID: 24382545 [No Abstract] [Full Text] [Related]
36. Palivizumab prophylaxis during respiratory syncytial virus outbreak in the neonatal intensive care unit. Alan S; Cakır U; Erdeve O; Atasay B; Arsan S Turk J Pediatr; 2013; 55(2):237-8. PubMed ID: 24192692 [No Abstract] [Full Text] [Related]
37. [Effectiveness of passive immunisation against respiratory syncytium virus in a group of premature infants with birth weight below 1000 grams]. Korbal P; Mikołajczak A; Szymański W Ginekol Pol; 2003 Oct; 74(10):1154-9. PubMed ID: 14669411 [TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey: author's reply. Oncel MY; Alyamaç-Dizdar E; Erdeve O; Oğuz S; Dilmen U Turk J Pediatr; 2013; 55(5):568. PubMed ID: 24401320 [No Abstract] [Full Text] [Related]
39. Palivizumab prophylaxis during respiratory syncytial virus outbreak in neonatal intensive care unit: author's reply. Oncel MY; Dizdar EA; Dilmen U Turk J Pediatr; 2013; 55(2):239. PubMed ID: 24205516 [No Abstract] [Full Text] [Related]
40. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. ; Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]